Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586651 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
A Phase 2 study of Polycythemia Vera and Essential Thrombocytosis, sponsored by Cephalon.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 4
- Study locations
NCT00586651 is a Phase 2 study of Polycythemia Vera and Essential Thrombocytosis that has completed, run by Cephalon. The registered enrollment target is 39 participants, below the 339-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00586651, a Phase 2 study of Polycythemia Vera and Essential Thrombocytosis, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).
Conditions Studied
Interventions
- DRUG lestaurtinib
Study Locations (4)
New York
- NY Presbyterian-Cornell - New York
- Mount Sinai School of Medicine - New York
Maryland
- Johns Hopkins University - Baltimore
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586651
The ClinicalTrials.gov registry entry for NCT00586651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 339-participant average among 22 other Polycythemia Vera trials with a reported enrollment target (88% lower). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Polycythemia Vera appearing as the primary indexed condition, and to 1 intervention - of which lestaurtinib is the first listed.
NCT00586651 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00586651 about?
NCT00586651 is a clinical study titled "Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis". This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).
What is the current status of trial NCT00586651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2007-12. Estimated completion is 2010-09.
What conditions does trial NCT00586651 study?
This clinical trial studies the following conditions: Polycythemia Vera, Essential Thrombocytosis.
What interventions are being tested in trial NCT00586651?
The interventions under investigation include: lestaurtinib (DRUG).
Who is sponsoring clinical trial NCT00586651?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00586651 being conducted?
This trial has 4 study locations across Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycythemia Vera
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.